---
title: "辉瑞公司指控 Metsera 董事从诺和诺德获得了针对其 “不当行为” 的不正当、广泛赔偿。"
description: "辉瑞公司指控 Metsera 董事从诺和诺德获得了针对其 “不当行为” 的不正当、广泛赔偿。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/263812230.md"
published_at: "2025-10-31T21:53:10.000Z"
---

# 辉瑞公司指控 Metsera 董事从诺和诺德获得了针对其 “不当行为” 的不正当、广泛赔偿。

辉瑞公司指控 Metsera 董事从诺和诺德获得了针对其 “不当行为” 的不正当、广泛赔偿。

### Related Stocks

- [MTSR.US - Metsera](https://longbridge.com/zh-CN/quote/MTSR.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Novo Nordisk A/S - share repurchase programme | Novo Nordisk A/S has initiated a share repurchase programme of up to DKK 15 billion, starting from 4 February 2026. As o | [Link](https://longbridge.com/zh-CN/news/276056741.md) |
| Novo Nordisk to Manufacture Wegovy in Ireland Facility | Novo Nordisk to Manufacture Wegovy in Ireland Facility | [Link](https://longbridge.com/zh-CN/news/275789396.md) |
| Berenberg Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU) | Berenberg Bank analyst Kerry Holford has reaffirmed a Buy rating on Novo Nordisk (0QIU) with a price target of DKK360.00 | [Link](https://longbridge.com/zh-CN/news/275719942.md) |
| Novo Nordisk Gets European Commission Approval for Higher-Dose Wegovy Injectable | 09:25 AM EST, 02/17/2026 (MT Newswires) -- Novo Nordisk ( NVO ) said Tuesday the European Commission has approved a 7.2  | [Link](https://longbridge.com/zh-CN/news/276138110.md) |
| EU approves higher dose of Novo's Wegovy | The European Commission has approved a higher dose of Novo Nordisk's popular weight-loss drug Wegovy, the Danish drugmak | [Link](https://longbridge.com/zh-CN/news/276134250.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。